Skip to main content

NCBiotech News

  • Novo Nordisk has officially begun building a $1.8 billion production facility for diabetes medicines at its Clayton site that will create 700 high-paying jobs, doubling its workforce there.
  • Morris Clarke, Ph.D., associate professor of biochemistry at Winston-Salem State University, has been named leader of the Executive Council of the Advisory Committee for Biotechnology in the Piedmont Triad as new members also join the advisory committee.
  • Duke University has purchased an exclusive sublicense from former NC biotech company PhaseBio Pharmaceuticals to use some of the firm's technology in developing long-acting cancer drugs with minimal toxic side effects.
  • Doug Edgeton, president and CEO of the North Carolina Biotechnology Center, is among a dozen corporate leaders nominated for a 2016 “Full Steam Ahead” award in a contest sponsored by WRAL TechWire.
  • Morrisville-based Envisia Therapeutics, a clinical-stage biotechnology company focused on developing novel therapies for eye diseases, has raised $16.5 million in additional Series A financing from existing investors.
  • Braeburn Pharmaceuticals, a 4-year-old Princeton, N.J., company developing drugs with specialized delivery technologies to improve treatments for mental illness, pain and addiction, plans to invest nearly $20 million over five years to establish a manufacturing and R&D hub in Durham that will create 52 new jobs.
  • Craft Technologies, a small contract laboratory in Wilson, has received $844,395 from the Bill & Melinda Gates Foundation for analytical work aimed at improving nutrition in the developing world.
  • Almac Group, a global CRO based in Northern Ireland, has opened a new development facility for companion diagnostics in Durham.
  • A family-owned German company called Raumedic has opened a $27 million development and production facility in western North Carolina to make medical and pharmaceutical plastic and rubber components.
  • Blood therapeutics company Grifols said it will invest $210 million to build two new facilities at its Clayton campus.
  • The federal faucet is opening again to pour $25.5 million into solithromycin, a promising drug being developed by Cempra, a Chapel Hill company that has declared war on bacterial infections.  
  • Durham-based BioCryst Pharmaceuticals might have a Zika bazooka on its hands, because the company’s experimental broad spectrum antiviral drug BCX4430 saved the lives of a batch of lab mice whose immune systems were deliberately suppressed before they were infected with Zika virus.
  • OncoTAb, a Charlotte company developing cancer diagnostics technologies with help from a North Carolina Biotechnology Center loan, is the only North Carolina life science company among the 60 startups and emerging companies have made the cut to present at this year’s Southeast Venture Conference.
  • NCBiotech President and CEO Doug Edgeton did some prognosticating at a luncheon briefing preceding Tuesday’s opening of the two-day 2016 CED Life Science Conference at the Raleigh Convention Center, presented each year by CED in partnership with NCBiotech and NCBio.
  • Leaders of four NCSU life science spinouts shared their growing pains and triumphs with more than 100 people gathered in a ballroom at the Raleigh Convention Center during a pre-conference panel discussion to kick off the 2016 CED Life Science Conference.
  • Innovate Biopharmaceuticals of Raleigh has completed an agreement to license all of Alba Therapeutics’ assets relating to larazotide acetate, a drug candidate progressing toward phase three clinical trials for the treatment of celiac disease.
  • West Pharmaceutical Services, a global designer and manufacturer of pharmaceutical packaging and delivery systems, will invest $19 million to upgrade its production plant in Kinston.
  • Precision BioSciences, a 2006 Duke University spin-out with a unique method to target and alter DNA, has signed a development deal with Baxalta that could bring the Research Triangle Park biotechnology company up to $1.6 billion.
  • Durham-based Bioventus has signed a multi-year agreement with IBSA (Institut Biochimique SA), a Swiss pharmaceutical company, to secure the exclusive U.S. distribution rights for GELSYN-3, a three-injection, hyaluronic acid product for pain relief from osteoarthritis of the knee.
  • North Carolina voters will not only cast ballots for their favorite presidential candidate in the March 15 primary election. They will also decide a $2 billion state bond referendum that has long-term implications for North Carolina’s life science community.

Pages

Subscribe to News & Events